The Advisory Committee on Immunization Practices (ACIP) has approved its immunization schedule for adults aged 19 years or older in the United States. The schedule summarizes ACIP recommendations in 2 figures, footnotes for the figures, and a table of contraindications and precautions for vaccines recommended for adults. Changes in the 2017 adult immunization schedule from the previous year include new or revised ACIP recommendations for influenza, human papillomavirus (HPV), hepatitis B, and meningococcal vaccine. Among the schedule changes (see ACIP schedule for complete recommendations):

Influenza vaccination:

• LAIV should not be used during the 2016–2017 influenza season.

HPV vaccination:

• Healthy adolescents who start their human papillomavirus (HPV) vaccination series before age 15 years are recommended to receive 2 doses of HPV vaccine. Adults and adolescents who did not start their HPV vaccination series before age 15 years should receive 3 doses of HPV vaccine.

Hepatitis B vaccination:

• Adults with chronic liver disease, including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than twice the upper limit of normal should receive a Hep B series.

Meningococcal vaccination:

• There are 2 changes in meningococcal vaccination recommendations for 2017.

• First, the ACIP recommended that adults with human immunodeficiency virus (HIV) infection receive a 2-dose primary series of serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY).
• Second, the ACIP provided updated dosing guidance for 1 of the serogroup B meningococcal vaccines (MenB) (MenB-FHbp [Trumenba, Pfizer]). 3 doses of MenB-FHbp should be administered at 0, 1–2, and 6 months to adults who are at increased risk for meningococcal disease, and those who are vaccinated during serogroup B meningococcal disease outbreaks. When MenB-FHbp is given to healthy adolescents and young adults who are not at increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months (MenB-FHbp was previously recommended as a 3-dose series at 0, 2, and 6 months, consistent with the original vaccine licensure for this population). The dosing frequency and interval for the other MenB, MenB-4C (Bexsero, GlaxoSmithKline), have not changed: MenB-4C remains a 2-dose series, with doses administered at least 1 month apart. Either MenB vaccine can be used when vaccination is indicated. The change in ACIP recommendations on the use of MenB-FHbp does not imply a preference for one MenB over the other.